Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,760,160
  • Shares Outstanding, K 169,409
  • Annual Sales, $ 4,110 K
  • Annual Income, $ -119,360 K
  • 60-Month Beta 1.08
  • Price/Sales 418.17
  • Price/Cash Flow N/A
  • Price/Book 5.37
Trade INO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.26
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.26 +25.79%
on 11/09/20
12.94 -19.71%
on 11/16/20
-0.56 (-5.11%)
since 10/23/20
3-Month
8.26 +25.79%
on 11/09/20
18.69 -44.41%
on 09/22/20
-2.23 (-17.67%)
since 08/25/20
52-Week
2.28 +355.70%
on 12/06/19
33.79 -69.25%
on 06/26/20
+7.79 (+298.85%)
since 11/25/19

Most Recent Stories

More News
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)

, /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today...

INO : 10.39 (+2.36%)
Thinking about trading options or stock in Pfizer, Inovio Pharmaceuticals, Alibaba, General Electric, or Nio?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, INO, BABA, GE, and NIO.

INO : 10.39 (+2.36%)
BABA : 277.72 (-0.80%)
GE : 10.50 (+0.48%)
NIO : 53.69 (+0.34%)
PFE : 36.53 (-0.19%)
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting

, /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced...

INO : 10.39 (+2.36%)
COVID-19 Vaccine & Therapeutics Clinical Trial Analysis Report 2020

The "COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020" report has been added to ResearchAndMarkets.com's offering.

HTBX : 1.1000 (+15.79%)
INO : 10.39 (+2.36%)
NVAX : 102.60 (+7.63%)
Vitally Important COVID-19 Test Kit Market Could Exceed $15 Billion This Year Alone

, /PRNewswire/ --The pandemic has wreaked havoc across the healthcare industry, and has led medical researchers to redirect all their might towards developing test kits and antidotes for coronavirus....

GWHP : 1.2400 (-7.46%)
MRNA : 109.18 (+10.78%)
INO : 10.39 (+2.36%)
SRNE : 6.90 (+1.77%)
JNJ : 143.68 (-0.13%)
Thinking about buying stock in Pfizer, Moderna, Inovio Pharmaceuticals, AMC Entertainment, or HighPoint Resources?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, INO, AMC, and HPR.

AC : 37.53 (-2.32%)
INO : 10.39 (+2.36%)
MRNA : 109.18 (+10.78%)
AMC : 4.49 (-1.97%)
HPR : 9.91 (+17.28%)
PFE : 36.53 (-0.19%)
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense

, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced...

INO : 10.39 (+2.36%)
More Comprehensive Diagnostics are Needed as Cases Surge Once More

, /PRNewswire/ -- The pandemic is in full swing once again; the daily U.S. death toll crossed the 2,000 mark on Wednesday as weeks of rising infection rates are now manifesting in mortality numbers not...

TOMDF : 0.0575 (-1.54%)
AMRN : 4.60 (+2.68%)
INO : 10.39 (+2.36%)
CODX : 12.14 (+14.96%)
ALT : 10.09 (+9.08%)
Is the Options Market Predicting a Spike in Inovio (INO) Stock?

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

INO : 10.39 (+2.36%)
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments

, /PRNewswire/ -- Academia and industry around the world are working from basic research to advanced technology to alleviate the effects of the COVID–19 health crisis. The application of nanoscience...

NNVC : 3.61 (-0.28%)
INO : 10.39 (+2.36%)
ALT : 10.09 (+9.08%)
LLY : 144.75 (-0.10%)
PFE : 36.53 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

2nd Resistance Point 11.55
1st Resistance Point 10.97
Last Price 10.39
1st Support Level 9.93
2nd Support Level 9.47

See More

52-Week High 33.79
Fibonacci 61.8% 21.75
Fibonacci 50% 18.03
Fibonacci 38.2% 14.32
Last Price 10.39
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar